A tool under investigation to personalize endocrine therapy in patients with unilateral ER + human epidermal growth factor 2-negative (HER2-) breast cancer is contralateral parenchymal enhancement (CPE) on dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI). Here, ERBB2 is linked to breast carcinoma.